Qiagen (QGEN) Given Buy Rating at Deutsche Bank

Qiagen (NASDAQ:QGEN)‘s stock had its “buy” rating reissued by research analysts at Deutsche Bank in a report issued on Monday.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Qiagen from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Cowen reissued a “hold” rating and set a $34.00 target price on shares of Qiagen in a research report on Thursday, December 21st. DZ Bank reissued a “neutral” rating on shares of Qiagen in a research report on Tuesday, December 19th. TheStreet raised Qiagen from a “c+” rating to a “b+” rating in a research report on Tuesday, November 7th. Finally, Commerzbank reissued a “buy” rating on shares of Qiagen in a research report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $34.63.

Shares of Qiagen (QGEN) opened at $32.87 on Monday. The stock has a market capitalization of $7,502.05, a PE ratio of 84.28, a PEG ratio of 1.83 and a beta of 1.10. Qiagen has a 1 year low of $27.51 and a 1 year high of $36.34. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78.

Qiagen (NASDAQ:QGEN) last released its earnings results on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.32. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The business had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. During the same period last year, the business earned $0.29 earnings per share. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. sell-side analysts predict that Qiagen will post 1.25 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in QGEN. Meag Munich Ergo Kapitalanlagegesellschaft lifted its stake in Qiagen by 1.4% during the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft now owns 266,600 shares of the company’s stock worth $6,309,000 after purchasing an additional 3,600 shares during the period. Manning & Napier Advisors lifted its stake in Qiagen by 5.0% during the fourth quarter. Manning & Napier Advisors now owns 2,857,499 shares of the company’s stock worth $79,009,000 after purchasing an additional 137,346 shares during the period. Capstone Asset Management Company lifted its stake in Qiagen by 8.6% during the fourth quarter. Capstone Asset Management Company now owns 150,489 shares of the company’s stock worth $4,161,000 after purchasing an additional 11,889 shares during the period. Acadian Asset Management lifted its stake in Qiagen by 22.7% during the fourth quarter. Acadian Asset Management now owns 199,694 shares of the company’s stock worth $5,523,000 after purchasing an additional 36,920 shares during the period. Finally, Russell Frank Co lifted its stake in Qiagen by 71.0% during the fourth quarter. Russell Frank Co now owns 984,835 shares of the company’s stock worth $27,160,000 after purchasing an additional 408,983 shares during the period. Hedge funds and other institutional investors own 62.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Qiagen (QGEN) Given Buy Rating at Deutsche Bank” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/22/qiagen-qgen-given-buy-rating-at-deutsche-bank.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply